Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11 – StreetInsider.com

Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11
StreetInsider.com
“The prevalence of childhood asthma in the U.S. is high, at more than six million patients, and that number continues to rise,” said Dr. Erwin Gelfand, Chairman, Department of Pediatrics at National Jewish Health. “For this young population of asthma

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *